Vincenzo Libri is a Clinical Senior Lecturer within the Division of Investigative Science at Imperial College London and Head of Clinical Studies at the ‘Sir John McMichael’ Clinical Research Centre - Hammersmith Campus. He also coordinates a MRes in Translational Medicine for graduates in medicine and basic scientists with a degree in life sciences.
From 1990 to 1998 he was a Welcome Trust and Medical Research Council Grant Holder at the School of Pharmacy, University of London (UK). In 1994 he was appointed Lecturer in Clinical Pharmacology at the University of Rome, (Italy). In the last ten years, Vincenzo has worked in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly, and GlaxoSmithKline) undertaking direct responsibilities for phase I/II clinical trials. In 2004 he was appointed Head of Experimental and Translational Medicine at the Department of Clinical Pharmacology and Discovery Medicine, Neurology CEDD, GSK-UK.
Dr Libri joined Imperial College in April 2009 to lead a team of clinicians, nurses and administrative staff and coordinate the development of a sustainable portfolio of clinical trials and experimental medicine studies across therapeutic areas. He is a Principal Investigator for the development and implementation of Phase I/II clinical trials in healthy volunteers and patients, with primary interests in experimental neurology, translational medicine and clinical neuro-pharmacology.
et al., 2021, Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial, The Lancet, Vol:398, ISSN:0140-6736, Pages:2277-2287
et al., 2021, Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial., The Lancet Respiratory Medicine, ISSN:2213-2600
et al., 2021, Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial, The Lancet, ISSN:0140-6736
et al., 2021, Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial, The Lancet, ISSN:0140-6736
et al., 2021, AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire., Sci Transl Med, Vol:13